Progress of CD73 in tumor immune microenvironment
10.3760/cma.j.issn.1006-9801.2019.01.015
- VernacularTitle:CD73在肿瘤免疫微环境中的研究进展
- Author:
Wenli YUE
1
;
Tongde TIAN
;
Tongliang TIAN
;
Yun CUI
;
Yixiao FAN
Author Information
1. 郑州大学附属肿瘤医院中西医结合科 450008
- Keywords:
5 '-nucleotidase;
Antibodies;
monoclonal;
Programmed death 1;
Tumor microenvironment;
Immunotherapy
- From:
Cancer Research and Clinic
2019;31(1):62-65
- CountryChina
- Language:Chinese
-
Abstract:
Extracellular 5'-nucleotidase (CD73) is not only highly expressed in a variety of solid tumor tissues, but also closely related to tumor stage, treatment and tumor prognosis. CD73 can exert a wide range of immunosuppressive effects through multiple pathways such as A2A receptor, regulation of regulatory T cells, and inhibition of inflammation. Blocking CD73 molecules can not only effectively activate anti-tumor immune responses, but also significantly improve the clinical efficacy of programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) antibodies. Thus, CD73, as a new immunological checkpoint molecule in the tumor microenvironment, may become a promising new immunotherapy target following CTLA4, PD-1/PD-L1.
